Lotem, M. Et Al. 2016. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. JOURNAL OF IMMUNOLOGY RESEARCH , vol.2016 .

Lotem, M., Merims, S., Frank, S., Hamburger, T., Nissan, A., Kadouri, L., ... Cohen, J.(2016). Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. JOURNAL OF IMMUNOLOGY RESEARCH , vol.2016.

Lotem, Michal Et Al. "Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade," JOURNAL OF IMMUNOLOGY RESEARCH , vol.2016, 2016

Lotem, Michal Et Al. "Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade." JOURNAL OF IMMUNOLOGY RESEARCH , vol.2016, 2016

Lotem, M. Et Al. (2016) . "Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade." JOURNAL OF IMMUNOLOGY RESEARCH , vol.2016.

@article{article, author={Michal Lotem Et Al. }, title={Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade}, journal={JOURNAL OF IMMUNOLOGY RESEARCH}, year=2016}